title: Synovectomy with rifampicine in haemophilic haemarthrosis.
abstract: The purpose of this paper was to assess the effectiveness of intra-articular injected rifampicine in haemophilic patients in order to achieve synovectomy by preventing repeated intra-articular bleeding. We have used this technique in haemophilic patients previously and reported our results on 13 cases [1]. Two hundred and fifty milligrams of rifampicine was injected into the elbow and ankle joints and 500 mg was injected into knee joints with 3-10 mL of lidocaine, depending on the joint size. The injections were repeated once a week for 7 weeks. Patients were only covered with antihaemophilic factor on the day of the injection at 30% above their coagulation level. We evaluated the results using two measures: subjective reports from the patient and objective assessment by the examiner. In the subjective reports the patient graded the results from their own perspective from 1 (poor) to 10 (excellent): 1-3, poor; 4-6, fair; 7-8, good; and 9-10, excellent. In the objective reports the grading was: excellent ('dry joint', full function, no haemarthrosis, no synovitis); good (clinical improvement, synovitis, reduction of haemarthroses, full function); fair synovitis (reduction of haemarthroses, no change in function); poor synovitis (persistent haemarthroses). This paper reports on the results of 38 patients with 39 joints with more that 3 years follow up, mean 1.8 years. There were 22 knees, nine elbows and eight ankles. Subjectively, there were excellent results in 21 joints (11 knees, six elbows and four ankles) good results in 15 joints (eight knees, three elbows and four ankles), fair results in two knees and a poor result in one knee. Objectively, results obtained were excellent in 20 joints (11 knees, six elbows and three ankles); good in 17 (nine knees, three elbows and five ankles); fair in one knee and poor in one knee.
authors.affiliation: Orthopaedic Unit, National Hemophilia Treatment Center, Municipal Blood Bank, Caracas, Venezuela. feferpal@telcel.net.ve
authors.forename: F
authors.initials: F
authors.lastname: Fernandez-Palazzi
authors.forename: S
authors.initials: S
authors.lastname: Rivas
authors.forename: R
authors.initials: R
authors.lastname: Viso
authors.forename: N B
authors.initials: NB
authors.lastname: de Bosch
authors.forename: A R
authors.initials: AR
authors.lastname: de Saez
authors.forename: A
authors.initials: A
authors.lastname: Boadas
mesh_terms: D000293:Adolescent; D000328:Adult; D000933:Antifibrinolytic Agents / Q000592:standards / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D006395:Hemarthrosis / Q000188:drug therapy* / Q000209:etiology; D006467:Hemophilia A / Q000150:complications* / Q000628:therapy; D006801:Humans; D007270:Injections, Intra-Articular / Q000379:methods / Q000592:standards; D008297:Male; D017063:Outcome Assessment, Health Care; D017060:Patient Satisfaction; D012293:Rifampin / Q000592:standards / Q000627:therapeutic use*; D000074402:Synovectomy; D013583:Synovial Membrane / Q000528:radiation effects*
chemical_list: D000933:Antifibrinolytic Agents; D012293:Rifampin